| Health / Medical Topics |
NA17.A2 Peptide Vaccine
A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas. (NCI Thesaurus)
YOU MAY ALSO LIKE
A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. When administered in a vaccine formulation, NA17-A antigen…
A synthetic peptide vaccine derived from the melanoma antigen NA17. Dendritic cells (DC) harvested from a cancer patient may be exposed to…
Sodium ion requiring one electron to return to its elemental state.
A peptide cancer vaccine consisting of peptides derived from the melanoma antigen NA-17, the human leukocyte antigen HLA-A2-restricted human melanoma antigen 3…
A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N4 TNM finding…
A general term that refers to a TNM finding of cancer metastases in multiple lymph nodes. The definition of N3c TNM…
